Outlook Therapeutics, Inc. (OTLK) financial statements (2021 and earlier)

Company profile

Business Address 7 CLARKE DRIVE
CRANBURY, NJ 08512
State of Incorp. DE
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments181400212
Cash and cash equivalents181400212
Assets held-for-sale, not part of disposal group11     
Other undisclosed current assets5552221
Total current assets:7141922313
Noncurrent Assets
Finance lease, right-of-use asset2   
Operating lease, right-of-use asset0   
Property, plant and equipment131415161820
Other noncurrent assets1000001
Total noncurrent assets:441415161921
TOTAL ASSETS:10173317192234
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities99912111212
Accounts payable3235543
Accrued liabilities5545566
Taxes payable2222222
Debt0111011
Due to related parties4      
Other undisclosed current liabilities7111314162020
Total current liabilities:20202327283232
Noncurrent Liabilities
Long-term debt and lease obligation4033344
Long-term debt, excluding current maturities0000000
Finance lease, liability3   
Capital lease obligations33334
Operating lease, liability0   
Liabilities, other than long-term debt12446444
Financial instruments subject to mandatory redemption, settlement terms, share value, amount8      
Other liabilities4443342
Derivative instruments and hedges, liabilities  021 2
Other undisclosed noncurrent liabilities0444543
Total noncurrent liabilities:1681113131111
Total liabilities:36283540404343
Temporary equity, carrying amount6555554
Stockholders' equity
Stockholders' equity attributable to parent(31)(16)(7)(28)(26)(26)(13)
Common stock0000111
Additional paid in capital240238238212202190190
Accumulated deficit(271)(254)(244)(240)(230)(216)(204)
Total stockholders' equity:(31)(16)(7)(28)(26)(26)(13)
TOTAL LIABILITIES AND EQUITY:10173317192234

Income statement (P&L) ($ in millions)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
Gross profit: 611111
Operating expenses(8)(19)(6)(8)(11)(13)(8)
Operating loss:(8)(13)(6)(8)(10)(12)(7)
Interest and debt expense(9)(0)(2)(1)(1)(1)(1)
Loss from continuing operations before equity method investments, income taxes:(17)(13)(7)(9)(11)(14)(8)
Other undisclosed income (loss) from continuing operations before income taxes 02(1)21(0)
Loss from continuing operations before income taxes:(17)(13)(5)(10)(10)(13)(8)
Income tax benefit 31  0 
Net loss:(17)(10)(4)(10)(10)(12)(8)
Other undisclosed net income attributable to parent0      
Net loss attributable to parent:(17)(10)(4)(10)(10)(12)(8)
Preferred stock dividends and other adjustments(0)(0)(0)(0)(0)(0)(1)
Other undisclosed net loss available to common stockholders, basic(2)  (1) (0) 
Net loss available to common stockholders, diluted:(18)(10)(5)(11)(10)(13)(9)

Comprehensive Income ($ in millions)

12/31/2019
Q1
9/30/2019
Q4
6/30/2019
Q3
3/31/2019
Q2
12/31/2018
Q1
9/30/2018
Q4
6/30/2018
Q3
Net loss:(17)(10)(4)(10)(10)(12)(8)
Comprehensive loss, net of tax, attributable to parent:(17)(10)(4)(10)(10)(12)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: